CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03981146
NCT03981146Phase 2Completed
CompareCT.gov

A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

University of Birmingham·interventional·Posted Jun 10, 2019·Updated Apr 22, 2026

In Brief

A Phase 2 clinical trial evaluating Nivolumab for Colorectal Cancer. Completed, enrolled 35 participants across 14 sites.

Detailed Summary

An open-label, single-arm, phase II, multicentre clinical trial to determine the rate of durable clinical benefit of nivolumab in patients with class II expressing microsatellite stable colorectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited Kingdom
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 10, 2019
Enrollment StartAug 28, 2019
Primary CompletionNov 26, 2024
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.1 years ago

Interventions

Nivolumabdrug

60 Minute IV Infusion